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At present, the management of non-organ confined prostate cancer, whether it is a recurrence or metastasis,
continues to evolve based on prostate cancer detection using prostate-specific antigen and the development of
medications as alternatives for the classical orchiectomy, which induced irreversible implications for quality of life.
Diethylstilbestrol therapy was associated with cardiovascular side-effects; GnRH agonists were able to create a
castration level, but again considerable side-effects were described. Combination therapies using antiandrogens
and GnRH agonists do not improve survival and have additional toxicity. GnRH antagonists, which also suppress
FSH, represent the latest class of agents introduced for hormonal treatment, but phase III studies with survival
data are not yet available. In spite of all these achievements, hormonal manipulation has resulted in only modest
improvements during recent decades and new targets are needed to improve the clinical outcome. Selectively modi-
fying the androgen receptor is currently one of the most promising developments.
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Introduction
Huggins and Hodges (1941) described the androgendependent
nature of prostate cancer by the observation that surgical cas-
tration resulted in prompt relief of pain in patients with bone
metastatic prostate cancer, and since that time hormonal manipu-
lation in the treatment of prostate cancer has evolved.
To date, hormonal manipulation has been the keystone treat-
ment for patients whose localized prostate cancer has not been
treated effectively with surgery or radiation therapy. In advanced
disease, androgen deprivation therapy stabilizes .80% of the
patients. However, the median duration of the response after
initiating this hormonal regimen in metastatic disease is only
2–3 years! (Eisenberger et al., 1998).
It should be evident that the endocrine treatment of prostate
cancer is a palliative treatment. Convincing evidence for cure of
prostate cancer under endocrine treatment has rarely been pre-
sented. Manipulation of the male hormonal axis may result in
lower prostate-specific antigen (PSA) levels in patients with
androgen-insensitive tumours, but eventually the majority of
tumours will progress to a hormone refractory state with a
median survival of ,1 year (Nishimura et al., 2000).
Conventional management of nonorgan confined, recurrent or
metastatic prostate cancer is still evolving due to earlier diagno-
sis and new medications. In this review we describe the current
treatment strategies as well as the controversies related to the
hormonal therapy for advanced prostate cancer, such as mono-
therapy versus maximum androgen blockade, early versus
delayed hormonal therapy and intermittent versus continuous
hormonal treatment.
An important goal for chemoprevention is the maintenance of
an androgensensitive clinical state, and prevention and/or delay
of an androgenindependent state (Lieberman, 2001).
Working mechanism; biological basis of androgen
dependence/independence
The major source of androgens in the male is the Leydig cells
located at the testes. After castration, serum testosterone decreases
to 5–10% of the original values. The remaining testosterone is
derived from adrenal androgens, which may be metabolized to
testosterone and 5a-dihydrotestosterone (DHT), the most potent
androgen at the level of the prostate, which is derived from testo-
sterone through the activity of the enzymes 5a-reductase (5a-R)
type 1 and type 2. The biological activity of androgens is
determined by their structure and by their affinity to the androgen
receptor (AR), which is ,7-fold higher for DHT in comparison to
testosterone. Adrenal androgens are rather weak but can be metab-
olized to DHT within the prostate and outside through the avail-
ability of the enzymes 17b-hydroxysteroid dehydrogenase and
5a-R.
Androgen production in the Leydig cells and adrenals is under
pituitary control through LH and adrenocorticotrophic hormone
(Figure 1).
The action of androgens at the target cell is mediated by the
AR. The steroid–AR complex binds to specific DNA sites and
leads to the initiation of transcription. Without this receptor, ster-
oid hormones cannot exert their biological effect. Antiandrogens
interfere with the formation of the AR complex at the level of
the receptor.
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Several publications (Taplin et al., 1995, 1999; Tilley et al.,
1996) suggest that androgen ablation provides selective pressure
on the androgen signalling pathway for mutation development.
Androgen deprivation can be achieved by: surgical castration;
medical castration: estrogens, GnRH agonists and antagonists;
androgen blockade at target cells: steroidal antiandrogens, pure
antiandrogens, maximal androgen blockade and 5aR inhibition.
Prostate tissue shrinks if androgen is withdrawn by an average
of 30–40%. The possibility of relapse is best explained by the
presence of hormone-resistant cell populations, which through
clonal overgrowth eventually lead to the presence of a hormone-
insensitive tumour.
There is a pathological continuum starting with normal-
appearing glandular epithelium that evolves to dysplastic pro-
static intra-epithelial neoplasia (carcinoma in situ) and then to
invasive carcinoma. The early stages are androgen dependent.
However, as disease progresses over time, androgen independent
clones emerge, either de novo (stem cell theory) or in response
to androgen deprivation therapy and clonal selection
(Lieberman, 2001).
Five mechanisms to explain the antiandrogen resistant state
have been described (Patterson et al., 2002). (i) The hypersensi-
tive pathway: more AR is produced (by gene amplification) or
the AR has enhanced sensitivity to compensate for low androgen
levels, or more testosterone is converted to the more potent
DHT by 5a-R. (ii) The promiscuous pathway: the specificity of
the AR is broadened and it can be activated by nonandrogenic
molecules. This pathway may explain the clinical observation of
the antiandrogen withdrawal syndrome, in which patients who
progress on antiandrogen therapy tend to improve when anti-
androgens are stopped. (iii) The outlaw pathway: receptor
tyrosine kinases are activated, and the AR is phosphorylated by
either kinase B or the mitogenactivated protein kinase pathway,
producing a ligandindependent AR. (iv) The bypass pathway: par-
allel survival pathways, such as that involving the antiapoptotic
protein B-cell lymphoma 2, obviate the need for AR or its ligand.
(v) The lurker cell pathway: androgen-independent cancer cells
that are present in the prostate might be selected by therapy.
Considering these pathway theories, the current target of
antiandrogen therapy strategies is the creation of an androgen-
sensitive clinical state or to delay the androgen-independent
state.
Current approaches to hormonal treatment
In view of the hormonal pathway in men, several therapeutic
strategies have been proposed in recent decades.
Orchiectomy
The most logical way of reducing testosterone levels to castrate
levels is to perform an orchiectomy. This is a simple surgical
procedure and it results in a rapid reduction of circulating andro-
gen levels. However, it has no effect on the production or sup-
pression of FSH, which may continue to stimulate prostate
cancer cell growth. The procedure is irreversible and it will
inevitably lead to impotence.
Currently with the possibility of medical hormonal
blockade, simple orchiectomy is reserved for patients with
extensive bony metastases, at risk for spinal compres-
sion, bladder neck obstruction and retroperitoneal adenopathy
(Debruyne, 2002).
Figure 1. Endocrinologic pathway and antiandrogen effect. ACTH ¼ andrenocorticotrophic hormone; DHT ¼ dihydrotestosterone; FSH ¼ follicle
stimulating hormone; LH ¼ luteinizing hormone; LHRH ¼ luteinizing releasing hormone; þ ¼ stimulates; 2 ¼ inhibits.
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The profile of the prostate cancer patient has been changing
over the years, leading to earlier detection at younger age. These
patients are sexually and physically active and have a life
expectancy of .10 years, making quality of life issues increas-
ingly important while making a choice for treatment (Kolvenbag
et al., 2001).
Diethylstilbestrol (DES)
Treatment with DES achieves complete testosterone blockade by
blocking LH. It leaves FSH unaffected. The Veterans Adminis-
tration Cooperative Urological Research Group (VACURG) I
study (Byar and Corle, 1988) showed that the endocrine treat-
ment delays progression and also the time to progression
increased in non-metastatic disease. Because of the switch of the
majority of patients from the placebo arm to the endocrine treat-
ment arm at the time of progression, the findings do not exclude
the possibility of an effect of endocrine treatment on survival.
However, the side-effects are also well known; a 5 mg dose
was associated with increased mortality from cardiovascular
causes compared with castration (Blackard, 1975; Byar and
Corle, 1988), but low dose did show a decrease in cancer-related
death per year in high risk patients. However, de Voogt et al.
(1986) found in a total of 226 patients a lethal complication rate
of 16.1% with DES versus 7% in estramustine phosphate.
To avoid cardiovascular complication, a combination with
prophylactic aspirin was suggested; Rosenbaum et al. (2000)
treated patients with oral DES 1 mg three times daily or 2 mg
twice daily with aspirin 100 mg once daily. Of 18 patients, 66%
had PSA levels reduced to ,0.6 or had a $50% reduction.
Gynaecomastia was noted in 2 of 18 patients. No thrombo-
embolic complications were noted.
Estrogenic therapies induce secondary responses in patients
with an androgen-independent state of prostate cancer, which
suggests an additional mechanism of action besides that of sup-
pression of the pituitary–gonadal axis. Several studies (Smith
et al., 1998; Orlando et al., 2000; Shadidi et al., 2001) suggest
that DES can produce PSA responses in a significant proportion
of patients in an androgen-independent state of prostate cancer.
The mechanism is yet unclear but may represent a direct cyto-
toxic effect on the cells, probably by apoptotic mechanisms
(Robertson et al., 1996).
GnRH agonists
Treatment with GnRH analogues offers reversible medical
castration, with side-effects similar to those of orchiectomy.
Following an initial rise in LH and FSH due to the stimulation
of GnRH, prolonged occupation of the LH receptors in the pitu-
itary results in a reduction in testosterone to levels equivalent to
those seen after administration of DES. GnRH agonists do not
influence FSH with unknown implications since FSH stimulates
growth factors and may induce progress of prostate cancer.
The testosterone surge must be distinguished from tumour
flare. This surge is a hormonal increase in testosterone, LH or
FSH following GnRH agonist therapy. The flare phenomenon is
a clinical presentation of worsening of the symptoms such as
pain, which may or may not follow the surge but is not
described without the testosterone surge (Kuhn et al., 1989;
Thompson et al., 1990). The surge is reported in nearly all
patients receiving GnRH agonist therapy, leading to a transient
over-stimulation of receptors and a surge of testosterone
secretion within the first few days of therapy, while flare is
reported in 4–33% of patients, even up to 63% of those with
advanced disease (Kuhn et al., 1989).
Oefelein (1998) studied 13 patients to determine the duration
of androgen suppression (leuprolide) after a single 3 month
injection and found persisting castrate levels of testosterone in
10 of the 13 patients at 6 months and hypogonadal symptoms
persisting for a median of 13.6 months. Although an overwhelm-
ing majority of patients treated with GnRH agonists achieve cas-
trate levels of testosterone, some do not. In another study by
Oefelein and Cornum (2000), 5% of patients failed to reach a
serum testosterone ,50 ng/dl and 13% failed to reach
,20 ng/dl. In cases of hormonal-dependent prostate cancer, this
phenomenon may be of clinical significance and provides a
rationale for the use of antiandrogens in addition to GnRH
agonist. Sharifi et al. (1998) stated that a testosterone escape can
occur during GnRH analogue therapy in ,10% patients pro-
jected over an average course of treatment.
GnRH agonists are used in a variety of settings for patients
with prostate cancer. Despite their efficacy they are expensive.
Another well-known phenomenon is that when the patients are
diagnosed with advanced prostate cancer and treated with GnRH
agonist, most continue taking this medication indefinitely. Long-
term GnRH results in impaired testicular testosterone and leads
to low serum testosterone and PSA levels for a long time, even
after cessation of hormonal treatment (Pedraza and Kwart,
2003).
GNRH antagonists
GnRH antagonists work by directly inhibiting GnRH receptor
without any initial stimulation of GnRH. The physiological
response is a direct and rapid decrease in LH, FSH and testo-
sterone with no flare. Stricker (2001) investigated a GnRH
antagonist depot (abalerix, i.m. injections every 28 days) and not
only noticed a prostate gland volume reduction of 19–46%
depending on the initial volume, but also an immediate androgen
ablation within 4 weeks (72% at 8 days; reached castration
levels).
Completed phase II data showed a fast reduction of testo-
sterone level (and PSA levels) within 10 days in contrast to 30%
treated with GnRH analogues (Tomera et al., 2001) and when
therapy is stopped, a quick recovery in testosterone levels is
measured. No surge and no clinical flare are noticed and FSH is
suppressed. The expansion of indications for androgen depri-
vation, such as down-sizing or intermittent therapy, could pro-
vide many opportunities for their use. Despite these encouraging
advances, however, their routine use for advanced prostate can-
cer may depend on demonstration of a survival advantage in
avoiding flare and further phase III studies are needed to evalu-
ate their efficacy, compared to the GnRH analogue therapy.
Antiandrogens
Steroidal antiandrogens have progestational and antigonado-
trophic properties and, therefore, inhibit the release of LH,
decreasing serum testosterone levels and causing suppression of
libido and loss of erectile potency.
Endocrine therapy of prostate carcinoma
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Pure androgen (non-steroidal) therapy leads to LH increase in
endocrinologically intact males.
Non-steroidal antiandrogens are often used in conjunction
with orchiectomy to establish combined androgen blockade
(CAB). Non-steroidal antiandrogens act through competitive
inhibition of androgen binding at the receptor level, inhibiting
the action of androgens from adrenal glands and testis. Testoster-
one levels remain more or less stable, because LH production is
limited by an increase in serum estrogens (because of increased
availability of androgens for peripheral conversion when treated
with these agents). The primary advantage of these agents is the
preservation of sexual potency.
There are three non-steroidal antiandrogens: flutamide, niluta-
mide and bicalutamide, of which bicalutamide (Casodex; Astra
Zeneca) is the most extensively evaluated.
The tolerability of non-steroidal antiandrogens has been exten-
sively evaluated with bicalutamide appearing to have a more
favourable adverse effects profile than flutamide or nilutamide.
Hot flashes are less common with non-steroidal antiandrogens,
with gynaecomastia and breast pain being the most frequent
adverse events associated with monotherapy (Tyrrell et al.,
1998b; Boccardo et al., 1999; Iversen et al., 2000). Gastrointesti-
nal side-effects, such as diarrhoea and nausea, are more common
with flutamide. Hepatotoxity and asymptomatic elevations of
aminotransferases are also more likely to occur in flutamide
treatment (Wysowski and Fourcroy, 1996).
Available data suggest that breast pain by gynaecomastia during
treatment may be prevented by prophylactic irradiation. Gynaeco-
mastia is caused by an increase of estrogen-to-androgen activity
due to aromatization of testosterone by cytochrome P450,
especially in peripheral fat. Estrogen antagonists and aromatase
inhibitors (blocking the conversion of androgens to estrogens) may
also have a place in prophylactic treatment of gynaecomastia.
Treatment with tamoxifen 10 mg showed a reduction of flutamide-
induced breast pain and enlargement (Staiman and Lowe, 1997;
Serels and Melman, 1998).
Cyproterone acetate Androcur (CPA), is a steroidal antiandro-
gen, immediately effective and does not have the cardiovascular
side-effects seen with oral estrogens. Schro¨der et al. (2000) com-
pared flutamide and CPA in a prospective randomized study,
which did not confirm earlier data on cardiovascular
toxicity, although patients were selected as not having coronary
diseases. Side-effects were loss of libido and potency, which
developed slowly with a median time of 8–12 months; ,20%
of men remained potent for poorly understood reasons. Hot
flashes and gynaecomastia are rare in CPA therapy, and CPA at
dosages of 50–100 mg per day seems to prevent the hot flashes
that present frequently under GnRH agonist therapy or
castration. Also muscle wasting, osteoporosis and anaemia may
be less pronounced. However, current data are too inconclusive
to determine whether CPA is as effective as castration or the use
of GnRH agonists.
Monotherapy versus maximum androgen blockade
Boccardo et al. (1999) investigated the results of bicalutamide
(Casodex) monotherapy versus flutamide (Eulexin) and
goserelin in prostate cancer patients and found no difference
in survival outcome. Bicalutamide monotherapy, 150 mg once
daily, was compared to flutamide, 250 mg three times daily, in
combination with goserelin. This was studied in 220 patients,
half of whom had nonmetastatic disease. No statistically
significant differences in overall or progression-free survival
were noted. Quality of life issues were in favour of the mono-
therapy group.
Also, bicalutamide was found to be better tolerated than CAB
with flutamide.
Another study from Fourcade et al. (1998) compared the
effect and safety of bicalutamide (Casodex) 150 mg mono-
therapy with castration and nilutamide (Anandron) in metastatic
prostate cancer. In 235 patients, no differences were noted in
objective response or time to disease progression. However, time
to treatment failure was significantly longer in bicalutamide
monotherapy patients compared to those on CAB. Bicalutamide
was also better tolerated. Hot flushes were noted in 47% of CAB
patients compared to 11% of monotherapy patients. Gynaeco-
mastia and breast pain were the most frequent adverse events in
the bicalutamide group (37 and 33%), compared to 3 and 1.5%
in the CAB group.
In a meta-analysis Samson et al. (2002), comparing CAB with
monotherapy, there was no statistically significant difference
between survival in a subgroup of patients with a good prog-
nosis, whereas adverse effects leading to withdrawal from
therapy occurred more often with CAB.
Non-steroidal antiandrogen therapy as monotherapy was
described in a small study with nilutamide where the median
progression-free survival was 9 months with a median overall
survival of 23 months (Decensi et al., 1991). Flutamide as
monotherapy was compared with castration or CAB; in both
studies (Pavone-Macaluso, 1994; Boccon-Gibod et al., 1997)
there was a similar outcome to the compared therapy.
Bicalutamide monotherapy, 150 mg once daily, achieves a
PSA response similar to castration and is well tolerated (Tyrrell
et al., 1998a). Survival analyses in patients with M1 (metasta-
sizing) disease showed that Casodex 150 mg was less effective
than castration, although the survival advantage was only 6
weeks. However, a post hoc evaluation, however, showed that
PSA level at time of entry to the study was related to outcome,
and that PSA levels ,400 and M1 disease patients had a similar
outcome.
Kaisary et al. (2001), in a post hoc analysis of randomized
controlled trials for metastatic prostate cancer patients,
concluded that monotherapy with bicalutamide 150 mg/day
may be of benefit when PSA levels are ,400 ng/ml.
Especially for subjective response, the preservation of physical
activity and sexual interest monotherapy appeared to give a
significant advantage.
There are only limited data on the use of steroidal antian-
drogen monotherapy. Moffat (1990) randomized 137 patients
with no contraindications to DES:goserelin:CPA at 2:1:1, and
223 patients with proposed contraindications to DES:goserelin
or DES:CPA at 2:1. CPA-treated patients had a significantly
poorer median survival than goserelin in the first group but
not in the second. Thorpe et al. (1996) found that the CPA
was less effective than goserelin, but no survival data
were published. The only advantage of CPA over castration
appears to be the lower incidence of hot flushes when it is
prescribed.
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Early versus delayed hormonal therapy
The decision to start hormonal therapy is not only a decision
concerning the medical complications and survival benefit, but it
also involves quality of life issues and health costs.
Should treatment start directly at the time of diagnosis or
should the treatment be postponed until symptoms develop?
Several studies have been performed. The VACURG study
suggests that the hormonal treatment with DES could be delayed
until the development of symptoms (Byar, 1973), but the study
design was probably not good enough to support this statement:
patients progressing on placebo were eligible to cross over to
DES without changing the study arm. VACURG I reported that
patients with metastatic disease were randomized to 5 mg of
DES, 5 mg of DES and orchiectomy, orchiectomy alone, or
placebo. Patients were allowed to cross over to DES when pro-
gression occurred, but the original study arm was not adapted.
No differences in survival were seen between the treatment
arms. Patients in the DES group had a higher incidence of
cardiovascular death, but lower incidence of prostate cancer-
related death. In VACURG II, patients were randomized to three
different dose regimes (0.2, 1 and 5 mg DES) versus placebo
(Byar and Corle, 1988); there was a cross-over design, but
concerns about toxicity of DES therapy led to withholding
patients at DES 0.2 mg and placebo therapy from cross-over.
Therefore, this study more or less investigated hormonal
treatment versus placebo treatment, but some survival benefit of
hormonal treatment was seen.
More recent studies investigated treatment timing. In 1997,
the Medical Research Council (MRC Prostate Cancer Working
Party Investigators Group, 1997) presented their results on 938
patients with locally advanced or asymptomatic metastatic pros-
tate cancer. Patients were randomized to immediate or delayed
treatment with orchiectomy or GnRH analogue. Progression
from M0 to M1 disease and development of metastatic pain
occurred more rapidly in the deferred treatment patients. More-
over, skeletal-related events, ureteral obstruction and develop-
ment of extra-skeletal metastases were more common in this
group. A significant improvement in survival was detected in
patients without evidence of metastases. In those with metastatic
disease, there was no survival benefit, but there appeared to be
significantly fewer side-effects from their metastases when trea-
ted early.
When reviewing the data, as was performed by the group in
2000, the advantage for early treatment on survival in the 938
patients studied had disappeared. For the group without metas-
tases, still there was a benefit in cancer-specific survival for the
early hormonal treatment.
A major concern for the MRC study was whether patients in
the delayed treatment arm were allowed to progress too far,
before they were offered hormonal treatment, which can of
course create a bias for the outcome. The MRC study has been
criticized on other major issues: exact causes of death related to
prostate cancer were not clear; the data recovery occurred only
once a year and the presence or absence of metastases at a time
when PSA measurement was not routinely available in all UK
centres. The final conclusion this study provides is that early
hormonal treatment can prevent serious complications of meta-
static prostate cancer, but does not necessarily prolong survival.
Bolla et al. (2002) performed a study with 415 patients with
locally advanced prostate cancer. Randomization was performed
between radiotherapy and goserelin immediately for 3 years and
radiation therapy alone. With a median followup of 45 months,
the overall survival at 5 years was 79% in the combined group
versus 62% in the radiation group. Of the surviving patients free
of disease at 5 years, the difference between the combined group
and the radiotherapy group was 85 versus 48%!. Bolla et al. also
concluded that there was improved local control in locally
advanced prostate cancer when goserelin therapy was started
simultaneously with external beam radiotherapy.
A publication of the Radiation Therapy Oncology Group
(Pilepich et al., 1997) investigated the use of adjuvant goserelin
in radiated patients with locally advanced prostate cancer in 977
patients. They were randomly assigned to achieve external beam
radiotherapy alone (65–72 Gy) or external beam radiotherapy
combined with 3.6 mg goserelin administered s.c. every 4 weeks
beginning the last week of radiation and continuing until the first
sign of progression. The 5 year survival rate appeared to be 75%
in the adjuvant arm versus 71% in the radiotherapy arm
(P ¼ 0.52). However, patients with a poorly differentiated
tumour (Gleason 8–10) had a significantly better 5 year survival
(66 versus 55%, P ¼ 0.3). In this study the goserelin therapy
was started at the end of the radiation course, which might be
the explanation for the differences. The synergistic effect of hor-
monal therapy combined with radiation therapy upon apoptotic
activity could have played a role in the study by Bolla et al.
(2002).
Granfors et al. (1998) performed a study with 91 patients with
locally advanced prostate cancer. After pelvic node staging,
patients were randomized to receive external beam radiation
therapy or a combination of radiation therapy and orchiectomy.
When clinical progression occurred in the monotherapy group,
patients were treated with androgen ablation. Clinical data
showed 61% progression in the radiation group versus 31% in
the combination group (P ¼ 0.005). Cancer-specific death was
44 versus 27% (P ¼ 0.06). Combined treatment had favourable
outcome in the lymph node-positive patients whereas node-
negative patients showed no significant differences in survival
rate. Progression-free, disease-specific and overall survival rates
are better in patients with pelvic lymph node involvement in
prostate cancer when treated with androgen ablation therapy
combined with radiation therapy. Because the androgen ablation
is performed at the start of the treatment, these data are in favour
of early androgen deprivation.
Messing et al. (1999) studied data of 98 patients with prostate
cancer who were treated with radical surgery and had positive
pelvic lymph node dissection. Patients were randomized for
immediate antiandrogen therapy with goserelin or orchiectomy
or to be followed until disease progression. The study was
designed to recruit 204 patients, but was closed earlier because
there appeared to be a marked improvement in overall and can-
cer-specific survival in the group receiving early hormonal treat-
ment. At a median of 7.1 years follow-up, 15% of patients in the
immediate group died versus 35% in the observational group.
However, this study lacks reference pathology analyses; and it is
known that 85% of patients with Gleason scores .8 and posi-
tive lymph nodes at radical prostatectomy will develop distant
metastases within a period of 5 years (Cheng et al., 1998). So it
Endocrine therapy of prostate carcinoma
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could be that patients were unequally distributed according to
their prognostic factors upon entry to the study, which could
well affect the outcome in a relatively small number of patients.
Van Andel and Kurth (2003) evaluated the impact of bicaluta-
mide monotherapy on health-related quality of life in 91 patients
with lymph node-positive prostate cancer. Patients were random-
ized for immediate or delayed treatment when progression
occurred. Time to progression was significantly shorter in the
delayed treatment arm (33 versus 62 months) but no significant
differences were found in survival. Patients with androgen depri-
vation therapy experienced a worse overall health-related quality
of life, experienced more hot flushes and also showed worse sex-
ual, emotional and physical function.
Studies performed to compare early versus delayed hormo-
nal therapy in patients with metastatic disease suggest no clear
survival advantage overall. However, when patients are lymph
node positive there is an advantage of early hormonal treat-
ment to influence progression-free survival and quality of life.
A survival advantage in the early therapy regimen can be
expected in patients with poorly differentiated prostate carci-
noma (Denis et al., 1998; Newling, 2001; Patterson et al.,
2002).
When distant metastases occur, early hormonal treatment has
advantages, reducing the risk of related complications.
Intermittent versus continuous hormonal treatment
Intermittent androgen deprivation (IAD) therapy is proposed to
delay the time to tumour progression in patients with prostate
cancer due to castration therapy resistance. Other advantages
include reduction of side-effects, reduction of costs. IAD therapy
has been proposed as monotherapy in patients with advanced
prostate cancer, but could also be applied in men who failed
radical prostatectomy or radiation therapy by an increase in PSA
levels. It has been stressed that prostate carcinoma with neuro-
endocrine (NE) differentiation tends to be more aggressive and
resistant to hormonal therapy.
Serum levels of NE markers, particularly Chromogranin A
(CgA), could reflect the NE activity of prostate carcinoma. It
could be used during follow-up. Sciarra et al. (2003) demon-
strated that intermittent administration of triptorelin and fluta-
mide significantly reduced the increase in serum CgA during
CAB therapy. Intermittent therapy was given following the PSA.
The ‘off-treatment phase’ was initiated when PSA was
,0.4 ng/l. This study only hypothesized that the IAD therapy
may reduce the risk of NE hyperactivation in prostate cancer
during androgen deprivation. No information was given about
the clinical progression when comparing stable CgA cases and
cases in which CgA was increasing.
Serial PSA determinations make intermittent androgen sup-
pression possible by providing an easy way to determine the
tumour activity during the non-treatment episodes. Intermittent
hormonal therapy consists of a 6–9 month period of hormonal
suppression followed by a corresponding length of time without
hormonal therapy. When PSA levels reach threshold criteria,
androgen suppression is reactivated. Many reversible medical
therapies have been used to suppress testosterone intermittently
(Klotz et al., 1986; Goldenberg et al., 1995; Higano et al., 1996;
Horwich et al., 1998; Crook et al., 1999; Grossfeld et al., 2001).
These six phase II trials investigated the effect of the intermittent
hormonal therapy. Most of the reported cases used an 8 month
period of androgen blockage followed by a non-treatment period
in which PSA was monitored. Treatment varied between DES,
maximal androgen blockade and GnRH analogues and was
restarted most of the time at a PSA level of 10 ng/ml, but this var-
ied between studies. Significant recovery of libido was reported
in the off-treatment period in men with a normal libido prior to
initial treatment. With regard to the effectiveness of the reinsti-
tuted hormonal therapy in prior responders, the overall subjective
improvement in well-being was significant in all studies.
Figure 2. Stepwise treatment options stage by stage (according to TNM classification prostate carcinoma) for patients with prostate cancer. WW ¼ watchfull
waiting; P ¼ radical prostatectomy; RT ¼ radiotherapy; HT ¼ hormonal therapy.
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Intermittent treatment seems to deliver a better outcome in
terms of survival than continuous hormonal therapy, though
there have been no randomized trials so far.
Neoadjuvant hormonal therapy before radical
prostatectomy
When dealing with hormonal therapy regimens for non-organ-
confined prostate cancer, one must be aware that a potentially
curative treatment may fail when the disease is incompletely
resected or when micro-metastases are present at the time of
the surgery. Some series report positive margin rates of
.60% after radical prostatectomy in patients who were clini-
cally staged pre-operatively to have localized prostate cancer
(Jones, 1990; Rosen et al., 1992; Frazier et al., 1993; Trapasso
et al., 1994). With the availability and widespread use of
reversible forms of medical castration, several investigators
have postulated that hormonal ablative therapy before radical
prostatectomy could improve outcome. Evaluating the prospec-
tive randomized trials comparing neoadjuvant androgen abla-
tion before radical prostatectomy with radical prostatectomy
alone, each study showed a significant reduction in margin-
positive disease, decline in PSA and reduction of prostate
volume in patients receiving neoadjuvant therapy (Soloway
et al., 1995; Van Poppel et al., 1995; Goldenberg et al., 1996;
Hugosson et al., 1996; Labrie et al., 1997; Lee et al., 1997).
However, none of these studies reported a statistical improve-
ment of survival, seminal vesicle or lymph node invasion, or
biochemical disease-free interval at 3, 4 and 5 years after sur-
gery. The neoadjuvant regimen contained androgen ablative
therapy 6–12 weeks before surgery, and the duration of the
therapy might explain these results (Gleave et al., 1997,
2000a). Furthermore, the follow-up could be too short and the
identification of residual tumour is difficult after hormonal
treatment (Murphy et al., 1991; Bazinet et al., 1997).
Gleave et al. (2000b) reported that the neoadjuvant hormonal
therapy for a period of 8 months yielded maximal tumour
volume reduction, and in their uncontrolled study they described
lower than expected PSA progression rates at 5 years in these
patients.
A European 4 year follow-up study (European Study Group,
2000) did not show a lower PSA progression rate, but there was
a trend towards a better local control of cT2 tumours in the
neoadjuvant goserelinþflutamide-treated group. However, a sub-
sequently higher survival rate could not been demonstrated at
that time.
Currently, 3 months of neoadjuvant hormonal therapy is not
recommended and controlled studies evaluating a longer period
of hormonal neoadjuvant treatment are needed.
Conclusion
In the current treatment, strategies of prostate cancer hormonal
therapy strategies are well established (Figure 2). Since Huggins
and Hodges (1941) described the concept of hormonal depen-
dence of prostate cancer, no new real differences in therapeutic
approaches have been developed, although hormonal blockade
itself has improved. Orchiectomy led to irreversible impotence,
while DES treatment caused improvement in survival at the cost
of considerable cardiovascular toxicity. GnRH agonists alleviated
these drawbacks, but other problems such as hormone surge,
causing clinical flare, were described. The combination therapy
does not completely suppress androgens, has more side-effects
and has almost no survival benefit compared to antiandrogen
monotherapy.
GnRH antagonists cause androgen suppression as effectively
as orchiectomy without the side-effects of surge and hormone
flare, and act not only upon testosterone level but also upon
FSH.
In T3þ M0 disease, the choice at the moment is either GnRH
agonists or bicalutamide. Early hormonal therapy strategies do
not influence survival significantly but could reduce the risk of
skeletal-related events. However, in T3Nþ disease there is a
survival benefit.
New developments could be the use of less toxic agents and
more clinical use of GnRH antagonists. However, the most
promising would be the modulation of the AR itself, and many
different specific androgens receptor modulators are currently
under investigation.
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